Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2022-09-26 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Loss of share certificate
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 98 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. Given the lack of content, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2022-09-26 English
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer ....
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 98 characters) and contains only a digital signature with no substantive content or financial data. There is no indication of any report, announcement, or detailed information. Given the lack of content, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2022-09-26 English
ESOP/ESPS/SBEB Scheme
Share Issue/Capital Change Classification · 95% confidence The document is an official communication from Bliss GVS Pharma Ltd. to stock exchanges regarding the allotment of shares under the company's Employee Stock Options Plan (ESOP) 2019. It details the number of shares allotted, the increase in issued share capital, exercise price, lock-in period, and compliance with SEBI regulations. There is no financial performance data, earnings information, or management discussion. The document is an announcement of a share allotment event related to employee stock options, which is a capital change event. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a formal disclosure of capital change.
2022-09-15 English
We would like to inform you that, the ESOP Allotment Committee of the Company at its meeting held on September 15, 2022 has approved the allotment of 76,750 equity shares of face value ....
Share Issue/Capital Change Classification · 100% confidence The document is an official communication from Bliss GVS Pharma Ltd. to stock exchanges regarding the allotment of shares under the company's Employee Stock Options Plan (ESOP) 2019. It details the number of shares allotted, the increase in issued share capital, exercise price, lock-in period, and compliance with SEBI regulations. The document is an announcement of a share allotment event and capital change, not a full financial report or earnings release. It does not contain financial statements or management discussion but focuses on share capital changes due to ESOP exercise. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is not a brief notice but a formal announcement with detailed share allotment information.
2022-09-15 English
Loss of share certificate
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 99 characters) and contains only a digital signature with a date and time. There is no substantive content, financial data, or report information. It does not contain any report, announcement, or detailed information. Given the lack of content, this is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2022-08-30 English
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer ....
Regulatory Filings Classification · 100% confidence The document text is extremely short (only 99 characters) and contains only a digital signature with a date and time stamp. There is no substantive content, financial data, or report information. It does not contain any report, announcement, or detailed information. According to the rules, such a document is best classified as a Regulatory Filing (RNS) since it does not fit any other category and is likely a certification or attestation.
2022-08-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.